v3.23.3
Earnings (Loss) Per Common Share (Tables)
12 Months Ended
Jun. 30, 2023
Earnings (Loss) Per Common Share [Abstract]  
Schedule of Earnings (loss) Per Share, Basic and Diluted The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

Year Ended

June 30, 

2023

    

2022

Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations

$

(29,311)

    

$

(29,512)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

 

(88)

Net loss available to iBio, Inc. stockholders from continuing operations

$

(29,311)

$

(29,600)

Net loss available to iBio, Inc. stockholders from discontinued operations

$

(35,699)

$

(20,791)

Net loss available to iBio, Inc. stockholders - total

$

(65,010)

$

(50,391)

Basic and diluted denominator:

Weighted-average common shares outstanding

 

12,245

 

8,721

 

 

Per share amount - continuing operations

$

(2.39)

$

(3.39)

Per share amount - discontinued operations

$

(2.92)

$

(2.39)

Per share amount - total

$

(5.31)

$

(5.78)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:

June 30, 

    

2023

    

2022

(in thousands)

Stock options

 

292

 

622

Restricted stock units

    

248

    

51

Warrants

 

5,871

 

21

Series 2022 Preferred

*

Shares excluded from the calculation of diluted loss per share

 

6,411

 

694

* Less than 1,000